Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd International consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871-1888. Abstract
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870-884. Abstract
Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17:279-288. Abstract
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35. Abstract
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936. Abstract
Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21;4760-4766. Abstract
Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740-753. Abstract
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. Abstract

CPD

Implementing New Paradigms in Advanced HR-Positive, HER2-Negative Breast Cancer

Authors: Angelo DiLeo, MD, PhD
CPD Released: 12/23/2016
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/23/2017, 11:59 PM EST

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically hematologists and oncologists involved in the treatment of patients with breast cancer.

The goal of this activity is to improve physicians’ understanding regarding the treatment and management of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Upon completion of this activity, participants will:

Have greater competence regarding when to use a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with endocrine therapy for treating HR-positive, HER2-negative metastatic breast cancer patients
Have greater competence related to managing adverse effects associated with the use of CDK4/6 inhibitors in combination with endocrine therapy
Have greater competence regarding dosing regimens when prescribing a CDK4/6 inhibitor in combination with endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Angelo Di Leo, MD, PhD

Head, Medical Oncology Unit; Chair, Oncology Department, “Sandro Pitigliani” Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Disclosures

Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bayer HealthCare; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre; Roche

Steering Committee

Nadia Harbeck, MD, PhD

Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany

Disclosures

Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc

Javier Cortés, MD, PhD

Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Disclosures

Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Angelo Di Leo, MD, PhD

Disclosures

As listed above.

Stephen R.D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

Disclosures

Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc; Puma Biotechnology
Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc

Xavier Pivot, MD, PhD

Professor, Jean Minjoz University Hospital, Besancon, France

Disclosures

Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

Sunil Verma, MD, MSEd, FRCPC

Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Disclosures

Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Editor

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate CME Clinical Director

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

CPD Information

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Angelo Di Leo, MD, PhD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editor

Deborah Middleton, MS

Content Reviewer

Robert Morris, PharmD

CPD

Implementing New Paradigms in Advanced HR-Positive, HER2-Negative Breast Cancer

Target Audience and Goal Statement

Disclosures

Faculty

Angelo Di Leo, MD, PhD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editor

Deborah Middleton, MS

Content Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Implementing New Paradigms in Advanced HR-Positive, HER2-Negative Breast Cancer